

Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Pertuzumab/trastuzumab (Phesgo®) is indicated in combination with PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel	C50	00797a	Pertuzumab/ Trastuzumab (Phesgo®): ODMS 20/12/2022 PACLitaxel - Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Treatment is administered every 21 days in responding patients until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when trastuzumab and pertuzumab (Phesgo®) is administered.

Cycle 1: Pertuzumab/trastuzumab (Phesgo®) loading dose

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1	Pertuzumab/ trastuzumab (Phesgo®)	1200mg/600mg	SC (Observe for 30 minutes post injection ^a)	Over 8 mins	Cycle 1 only
2	1, 8, 15	PACLitaxel	80mg/m ²	IV infusion	250ml 0.9% NaCl over 1hr ^b	Cycle 1 only

^aPatients should be observed for injection-related reactions and hypersensitivity reactions. Observation period should start following administration of Phesgo® and be completed prior to any subsequent administration of chemotherapy. Any deviation should be noted in local policies.

^bPACLitaxel must be supplied in non-PVC containers and administered using non-PVC giving sets and through an in-line 0.22 µm filter with a microporous membrane. PACLitaxel should be diluted to a concentration of 0.3-1.2mg/ml.

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 1 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p style="text-align: center;"><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Cycle 2 and subsequent cycles

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1	Pertuzumab/ trastuzumab (Phesgo®)	600mg/600mg	SC (Observe for 15 minutes post injection ^a)	Over 5 mins if no adverse reactions	Every 21 days
2	1, 8, 15	PACLitaxel	80mg/m ²	IV infusion	250ml 0.9% NaCl over 1hr ^b	Day 1, 8, 15 of a 21 day cycle up to maximum of 8 cycles

^aPatients should be observed for injection-related reactions and hypersensitivity reactions. Observation period should start following administration of Phesgo® and be completed prior to any subsequent administration of chemotherapy. Any deviation should be noted in local policies.

^bPACLitaxel must be supplied in non-PVC containers and administered using non-PVC giving sets and through an in-line 0.22 µm filter with a microporous membrane. PACLitaxel should be diluted to a concentration of 0.3-1.2mg/ml.

ELIGIBILITY:

- Indications as above
- HER2 positive as demonstrated by a validated test method
- Life expectancy > 3months
- ECOG status 0-1
- LVEF ≥ 50%

EXCLUSIONS:

- Hypersensitivity to pertuzumab, trastuzumab, PACLitaxel, or any of the excipients
- Clinically significant cardiac disease (history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within previous 12 months)
- Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal infusion reaction with trastuzumab
- Significant hepatic dysfunction, contraindicating PACLitaxel
- Baseline neutrophil count < 1.5 x 10⁹/L
- Pregnancy
- Lactation

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- FBC, renal and liver profile
- Cardiac function (LVEF using ECHO or MUGA scan)

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 2 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Regular tests:

- FBC, renal and liver profile before each cycle
- MUGA scan or echocardiogram every 12 weeks during treatment with pertuzumab/trastuzumab (Phesgo®) and at completion of therapy. Where there are signs of cardiac impairment four to eight weekly checks may be more appropriate.

Disease monitoring:

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

Pertuzumab/trastuzumab (Phesgo®):

- None usually recommended. Doses are held or discontinued if unacceptable toxicity occurs. Please see Table 1 below for recommendations on resuming dosing pertuzumab and trastuzumab after a dose delay or missed doses.
- Patients may continue therapy during periods of reversible chemotherapy-induced myelosuppression but they should be monitored carefully for complications of neutropenia during this time.

Table 1: Delayed or missed doses of pertuzumab and trastuzumab (Phesgo®)

Time between two sequential infusions	Dose modification
<6 weeks	The maintenance dose of pertuzumab/trastuzumab (Phesgo®) 600 mg/600 mg should be administered as soon as possible. Thereafter, continue with the 3-weekly schedule.
≥6 weeks	A loading dose of pertuzumab/trastuzumab (Phesgo®) 1200 mg/600 mg should be re-administered followed by maintenance dose of pertuzumab/trastuzumab (Phesgo®) 600 mg/600 mg every 3 weeks thereafter.

Table 2: Switching from intravenous pertuzumab and trastuzumab administration to Phesgo®

Time since last dose	Dose of Phesgo®
<6 weeks	Administer as a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab and every 3 weeks for subsequent administrations.
≥6 weeks	Administered as a loading dose of 1200 mg pertuzumab/600 mg trastuzumab, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab every 3 weeks for subsequent administrations.

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PAclitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 3 of 9

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Haematological:

Table 3: Dose modifications for PACLitaxel for haematological toxicity

ANC (x10 ⁹ /L)		Platelets	Dose	Dose after neutropenic sepsis
≥ 1.5	and	> 90	80mg/m ²	65mg/m ²
*1-1.49	or	70-90	65mg/m ²	50mg/m ²
< 1	or	< 70	Delay and reduce next dose to 65mg/m ² or add G-CSF	Delay

Patients who cannot tolerate treatment after 2 dose reductions or require a treatment delay of greater than 2 weeks, should discontinue treatment.

* If ANC 1 to less than 1.5 and patient fit and well can consider full dose of 80 mg/m² at discretion of prescribing Consultant

Renal and Hepatic Impairment:

Table 4: Dose modification in renal and hepatic impairment

Drug	Renal Impairment	Hepatic Impairment			
Pertuzumab/ trastuzumab (Phesgo®)	Dose adjustments are not needed in patients with mild or moderate renal impairment. No dose recommendations can be made for patients with severe renal impairment because of the limited pharmacokinetic (PK) data available.	The safety and efficacy have not been studied in patients with hepatic impairment. Patients with hepatic impairment are unlikely to require dose adjustment. No specific dose adjustment are recommended.			
PACLitaxel	No dose modifications necessary.	ALT		Total bilirubin	Dose of PACLitaxel
		< 10 x ULN	and	≤ 1.25 x ULN	80mg/m ²
		< 10 x ULN	and	1.26-2 x ULN	60mg/m ²
		< 10 x ULN	and	2.01-5 x ULN	40mg/m ²
		≥10 x ULN	and/or	>5 x ULN	Not recommended

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 4 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Management of adverse events:

Table 5: Dose modification schedule based on adverse events

Adverse reactions	Recommended dose modification
Pertuzumab/Trastuzumab (Phesgo®)	
LVEF < 40% or 40-45% associated with ≥10% points below the pre-treatment value.	Withhold treatment with pertuzumab/trastuzumab (Phesgo®). Repeat LVEF within 3 weeks. No improvement or further decline, consider discontinuation. Discuss with consultant and refer to cardiologist.
Symptomatic heart failure	Discontinue
NCI-CTCAE Grade 4 hypersensitivity reactions	Discontinue
PACLitaxel	
Grade >2 peripheral neuropathy	Decrease dose by 10mg/m ²
All other grade 2 non-haematological toxicity	Hold treatment until toxicity resolves to ≤ grade 1. Decrease subsequent doses by 10mg/m ² .
≥ Grade 3 reaction	Discontinue
Patients who cannot tolerate treatment after 2 dose reductions or require a treatment delay of greater than 2 weeks, should discontinue treatment.	

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Pertuzumab/trastuzumab (Phesgo®): Minimal (**Refer to local policy**)

PACLitaxel: Low (**Refer to local policy**)

PREMEDICATIONS:

Trastuzumab/pertuzumab (Phesgo®): Not usually required unless the patient has had a previous hypersensitivity. Paracetamol and antihistamine cover should be considered. Patient should be educated about the possibility of delayed infusion-related symptoms.

PACLitaxel:

- All patients must be premedicated with corticosteroids, antihistamines, and H₂ antagonists prior to first dose of PACLitaxel treatment.
- The H₂ antagonist, famotidine, can potentially be omitted from the pre-medication requirements for PACLitaxel but the risk of hypersensitivity with this approach is unknown.
 - Caution is advised particularly for patients receiving PACLitaxel every 3 weeks. It is recommended that if famotidine is omitted that patients are monitored closely for any signs of hypersensitivity. Any hypersensitivity should be managed as per local policy.

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 5 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

- Where a patient experiences hypersensitivity, consider the use of alternative H₂ antagonists (**Refer to local policy**).

Table 6 outlines the suggested premedications prior to treatment with PACLitaxel.

Table 6: Suggested premedications prior to treatment with PACLitaxel

Day of treatment	Drug	Dose	Administration prior to PACLitaxel
Day 1	dexAMETHasone ^a	8mg IV	30 minutes
Day 1	Chlorphenamine	10mg IV	30 minutes
Day 1	Famotidine	20mg IV	30 minutes
Day 8 ^b and thereafter	dexAMETHasone ^a	None	
Day 8 and thereafter	Chlorphenamine	10mg IV	30 minutes
Day 8 and thereafter	Famotidine ^c	20mg IV	30 minutes
^a Dose of dexAMETHasone may be altered, in the event of hypersensitivity reaction, to 20 mg of dexAMETHasone orally 12 hr and 6 hr prior to re-challenge with PACLitaxel according to consultant guidance.			
^b Dose of dexAMETHasone may be added from day 8 if increased risk or previous hypersensitivity reaction according to consultant guidance.			
^c Dose of famotidine may be omitted in the absence of hypersensitivity reaction according to consultant guidance.			

OTHER SUPPORTIVE CARE:

Myalgias and arthralgias may occur with PACLitaxel. Analgesic cover should be considered.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hypersensitivity/Infusion reactions:** There is a risk of hypersensitivity/infusion reactions with pertuzumab and PACLitaxel. Although hypersensitivity with trastuzumab is common, severe hypersensitivity reactions are uncommon. Use with caution in patients with dyspnoea at rest from pulmonary/cardiac conditions as increased risk of infusion related symptoms.

Pertuzumab/trastuzumab (Phesgo®)

- **Left ventricular dysfunction (including congestive heart failure):** The incidence of symptomatic left ventricular systolic dysfunction (LVD [congestive heart failure]) was higher in patients treated with pertuzumab in combination with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy. In the adjuvant setting, the majority of cases of symptomatic heart failure reported were in patients who received anthracycline-based chemotherapy. Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of LVEF declines based on studies with intravenous pertuzumab in combination with trastuzumab and chemotherapy. Phesgo® has not been studied in patients with: a pre-treatment LVEF value of < 55 % (EBC) or < 50 % (MBC); a prior history of congestive heart failure (CHF); conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m² of DOXOrubicin or its equivalent. In addition, pertuzumab in combination with trastuzumab and chemotherapy has not

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 6 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</p>		

been studied in patients with decreases in LVEF < 50 % during prior trastuzumab adjuvant therapy. Assess LVEF prior to initiation of Phesgo® and at regular intervals during treatment (e.g. once during neoadjuvant treatment and every 12 weeks in the adjuvant and metastatic setting) to ensure that LVEF is within normal limits. If the LVEF has declined and has not improved, or has declined further at the subsequent assessment, discontinuation of Phesgo® should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. Cardiac risk should be carefully considered and balanced against the medical need of the individual patient before use of Phesgo® with an anthracycline. Based on the pharmacological actions of HER2-targeted agents and anthracyclines, the risk of cardiac toxicity might be expected to be higher with concomitant use of Phesgo® and anthracyclines than with sequential use.

- Injection-related reactions/infusion-related reactions (IRRs):** Phesgo® has been associated with injection-related reactions. Close observation of the patient during and for 30 minutes after administration of the loading dose and during and for 15 minutes following the administration of the maintenance dose of Phesgo® is recommended. If a significant injection-related reaction occurs, the injection should be slowed down or paused and appropriate medical therapies should be administered. Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms. Permanent discontinuation should be considered in patients with severe injection-related reactions. This clinical assessment should be based on the severity of the preceding reaction and response to administered treatment for the adverse reaction. Although fatal outcomes resulting from injection-related reactions have not been observed with Phesgo®, caution should be exercised, as fatal infusion related-reactions have been associated with intravenous pertuzumab in combination with intravenous trastuzumab and chemotherapy.
- Hypersensitivity reactions/anaphylaxis:** Patients should be observed closely for hypersensitivity reactions. Severe hypersensitivity reactions, including anaphylaxis and events with fatal outcomes, have been observed with pertuzumab in combination with trastuzumab and chemotherapy. The majority of anaphylactic reactions occurred within the first 6-8 cycles of treatment when pertuzumab and trastuzumab were given in combination with chemotherapy. Medicinal products to treat such reactions, as well as emergency equipment, should be available for immediate use. Phesgo® must be permanently discontinued in case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm or acute respiratory distress syndrome. Phesgo® is contraindicated in patients with known hypersensitivity to pertuzumab, trastuzumab or to any of its excipients.
- Diarrhoea:** Phesgo® may elicit severe diarrhoea. Diarrhoea is most frequent during concurrent administration with taxane therapy. Elderly patients (≥ 65 years) have a higher risk of diarrhoea compared with younger patients (< 65 years). Treat diarrhoea according to standard practice and guidelines. Early intervention with loperamide, fluids and electrolyte replacement should be considered, particularly in elderly patients, and in case of severe or prolonged diarrhoea. Interruption of treatment with Phesgo® should be considered if no improvement in the patient’s condition is achieved. When the diarrhoea is under control treatment with Phesgo® may be reinstated.
- Pulmonary events:** Severe pulmonary events have been reported with the use of trastuzumab. These events have occasionally been fatal. These events may occur as part of an infusion-related reaction or with a delayed onset. Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of pulmonary events. Therefore, these patients should not be treated with Phesgo®. Caution should be exercised for pneumonitis, especially in patients being treated concomitantly with taxanes.
- Hypersensitivity/Infusion reactions:** There is a risk of hypersensitivity/infusion reactions with

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PAclitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 7 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

pertuzumab and PACLitaxel. Although hypersensitivity with trastuzumab is common, severe hypersensitivity reactions are uncommon. Use with caution in patients with dyspnoea at rest from pulmonary/cardiac conditions as increased risk of infusion related symptoms.

- **Cardiac toxicity:** Decreases in LVEF have been reported with medicinal products that block HER2 activity, including pertuzumab. Trastuzumab can produce declines in ventricular dysfunction and congestive heart failure (CHF). Baseline and three monthly cardiac function tests are required during treatment especially for those with prior anthracycline exposure.

PACLitaxel

- **Febrile neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Extravasation:** PACLitaxel causes pain and tissue necrosis if extravasated (**Refer to local policy**).
- **Peripheral neuropathy:** Occurs frequently but the development of severe symptoms is rare.
- **Arthralgia/myalgia:** May be severe in some patients; however, there is no consistent correlation between cumulative dose and infusion duration of PACLitaxel and frequency or severity of the arthralgia/myalgia. Symptoms are usually transient, occurring within 2 or 3 days after PACLitaxel administration, and resolving within days.
- **Hepatic dysfunction:** Patients with hepatic impairment may be at increased risk of toxicity, particularly grade 3-4 myelosuppression.
- **Cardiac conduction abnormalities:** If patients develop significant conduction abnormalities during PACLitaxel administration, appropriate therapy should be administered and continuous cardiac monitoring should be performed during subsequent therapy with PACLitaxel. Hypotension, hypertension, and bradycardia have been observed during PACLitaxel administration; patients are usually asymptomatic and generally do not require treatment. Frequent vital sign monitoring, particularly during the first hour of PACLitaxel infusion, is recommended.

DRUG INTERACTIONS:

- A possible interaction with warfarin has been reported. An increased INR and bleeding may occur in patients previously stabilised on warfarin. The interaction was noted in two patients after 8-10 doses of trastuzumab. An INR prior to starting the trastuzumab is recommended, then every 2 weeks for the first 3 months and then monthly if stable. Inform patient to watch for any bleeding. Modification of the warfarin dose may be needed.
- Risk of drug interactions causing increased concentrations of PACLitaxel with CYP3A inhibitors. Patients should also be counselled with regard to consumption of grapefruit juice.
- Risk of drug interactions causing decreased concentrations of PACLitaxel with CYP3A inducers.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

1. Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol 2015;33:442-47.
2. Bachelot, T., E. Ciruelos, T. Peretz-Yablonski, et al. First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE. ASCO Meeting Abstracts 2014;32(15_suppl):548.

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 8 of 9

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

3. Yu AF, Manrique C, Pun S, et al. Cardiac safety of paclitaxel plus trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer. *The Oncologist* 2016;21(4):418–24.
4. Tan A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. *Lancet Oncol.* 2021 Jan; 22(1):85-97.
5. Nissenblatt MJ, Karp GI. Bleeding risk with trastuzumab (Herceptin) treatment *JAMA* 1999;282:2299-301.
6. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V5 2023. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
7. Pertuzumab/Trastuzumab (Phesgo®) Summary of Product Characteristics. Accessed December 2022 https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf
8. PACLitaxel. Summary of Product Characteristics. Accessed December 2022. Available at http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0585-029-001_17122008223616.pdf

Version	Date	Amendment	Approved By
1	20/12/2022		Prof Maccon Keane
2	10/08/2023	Updated emetogenic potential of pertuzumab/trastuzumab (Phesgo®)	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: Pertuzumab /Trastuzumab (Phesgo®)and Weekly PACLitaxel Therapy– 21 day cycle	Published: 20/12/2022 Review: 20/12/2023	Version number: 2
Tumour Group: Breast NCCP Regimen Code: 00797	ISMO Contributor: Prof Maccon Keane	Page 9 of 9
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		